Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266262 | 0.96 | MEN1 (0.39) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL22266258 | 0.93 | TSHR (0.34) | TSHRMAPK1MEN1KMT2ACYP1A2 | |
| SCHEMBL22266320 | 0.89 | CYP1A2 (0.32) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22266278 | 0.87 | HDAC3 (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22266313 | 0.86 | HDAC3 (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22266268 | 0.86 | CYP1A2 (0.30) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22266274 | 0.86 | HDAC3 (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL20235114 | 0.83 | MAPK1 (0.37) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL22266282 | 0.81 | MEN1 (0.39) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL22266299 | 0.80 | TSHR (0.35) | TSHRMAPK1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | TSHR 2304/4885MAPK1 2843/4885MEN1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.